Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Partially Randomized, Placebo-controlled, Sequential Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum

NCT06990984 is registered in ClinicalTrials.gov with Thiogenesis Therapeutics, Inc. as lead sponsor.

NCT NCT06990984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06990984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Partially Randomized, Placebo-controlled, Sequential Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum
Lead sponsor
Thiogenesis Therapeutics, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
September 30, 2027
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

leigh syndrome